Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abiraterone acetate + prednisone
- Development stage
- Unknown
- Lead developer
- Janssen Biotech
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Abiraterone acetate + prednisone is an oral combination therapy used primarily for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Abiraterone acetate is a prodrug of abiraterone, a selective and irreversible inhibitor of Cytochrome P450 17A1 (CYP17A1), an enzyme critical to androgen biosynthesis. By inhibiting CYP17A1, abiraterone reduces androgen production in the testes, adrenal glands, and tumor tissue. Prednisone is co-administered as glucocorticoid replacement therapy to counteract mineralocorticoid excess and adrenal insufficiency caused by CYP17A1 inhibition. This combination improves overall survival and progression-free survival in men with mCRPC[2][3][5].
- Brand names
- YonsaAbiratasAbretoneAbirapro
- Other names
- abiraterone acetate + prednisone
02
Targets
CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on abiraterone acetate + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abiraterone acetate + prednisone.